Clinical Trial

Phase 1 Study of MST-168 in Participants With Advanced Solid Malignant Tumors

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
A Phase 1, multiregional, open-label study of MST-168 in participants with target-driven advanced solid tumors. The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamic effects, and preliminary efficacy of MST-168 in participants with target-driven advanced solid tumors. MST-168 is an investigational ADC.
Trial Details
NCT Number NCT07644650
Lead Sponsor Mabsoft Therapeutics (Shanghai) Co., Ltd.
Collaborators: Mabsoft Therapeutics (Australia) Pty. Ltd., Mabsoft Therapeutics (Guangdong Hengqin) Co., Ltd.
Conditions Neoplams
Enrollment 420 participants
Start Date 2026-06-15
Primary Completion 2028-06-30 (estimated)
Study Completion 2030-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-12